543 related articles for article (PubMed ID: 33256070)
1. Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer.
Mediratta K; El-Sahli S; D'Costa V; Wang L
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33256070
[TBL] [Abstract][Full Text] [Related]
2. Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y; Zhu X; Tang C; Guan X; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
4. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model.
Rahman A; Janic B; Rahman T; Singh H; Ali H; Rattan R; Kazi M; Ali MM
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894298
[TBL] [Abstract][Full Text] [Related]
7. Prospects of Immunotherapy for Triple-Negative Breast Cancer.
Qiu D; Zhang G; Yan X; Xiao X; Ma X; Lin S; Wu J; Li X; Wang W; Liu J; Ma Y; Ma M
Front Oncol; 2021; 11():797092. PubMed ID: 35111680
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
[TBL] [Abstract][Full Text] [Related]
10. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.
Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.
Yang T; Li W; Huang T; Zhou J
J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983708
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
13. Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer.
Ensenyat-Mendez M; Orozco JIJ; Llinàs-Arias P; Íñiguez-Muñoz S; Baker JL; Salomon MP; Martí M; DiNome ML; Cortés J; Marzese DM
Commun Med (Lond); 2023 Jul; 3(1):93. PubMed ID: 37430006
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract][Full Text] [Related]
16. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
[TBL] [Abstract][Full Text] [Related]
17. Role of Immunotherapy in Breast Cancer.
Jacob SL; Huppert LA; Rugo HS
JCO Oncol Pract; 2023 Apr; 19(4):167-179. PubMed ID: 36608303
[TBL] [Abstract][Full Text] [Related]
18. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
Front Oncol; 2022; 12():779786. PubMed ID: 35646659
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
